Intravascular large B-cell lymphoma involving hemangiomas: an unusual presentation of a rare neoplasm.
We report the clinicopathological features of two cases of intravascular large B-cell lymphoma involving cutaneous hemangiomas. The cases were identified from the consultation files of two of the authors. Both patients were women, 64 and 55 years of age, who presented with long-standing cutaneous hemangiomas of the posterior scalp and left shoulder, respectively. The lesions were brought to medical attention by an increase in size and change in color. Biopsies and immunohistochemical evaluation of the hemangiomas revealed extensive involvement by intravascular large B-cell lymphoma. The neoplastic cells were diffusely positive for CD20 in both cases and negative for CD3, pan-cytokeratin (AE1/AE3), epithelial membrane antigen, S-100, Factor VIII-related antigen, CD34 and CD31. Disease was limited to the hemangiomas in both patients. Treatment consisted of chemotherapy (both patients) and adjuvant radiation therapy (one patient). One patient had a recurrence of disease 33 months after initial diagnosis, leading to an autologous stem cell transplant. The other patient is without evidence of disease 27 months after initial diagnosis. Although this is a rare neoplasm, it is important to consider intravascular large B-cell lymphoma in the differential diagnosis of vascular lesions containing intravascular neoplastic cells.
Nixon
Brigitte K
BK
Department of Anatomic Pathology, University of Washington Medical Center, Seattle, WA 98195, USA.
Kussick
Steven J
SJ
Carlon
Michael J
MJ
Rubin
Brian P
BP
D018941:Antigens, CD19 / Q000032:analysis; D018951:Antigens, CD20 / Q000032:analysis; D018956:CD5 Antigens / Q000032:analysis; D004268:DNA-Binding Proteins / Q000032:analysis; D003937:Diagnosis, Differential; D005260:Female; D006391:Hemangioma / Q000378:metabolism / Q000473:pathology* / Q000628:therapy; D006801:Humans; D007150:Immunohistochemistry; D050835:Interferon Regulatory Factors; D017493:Leukocyte Common Antigens / Q000032:analysis; D016393:Lymphoma, B-Cell / Q000378:metabolism / Q000473:pathology* / Q000628:therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000378:metabolism / Q000473:pathology* / Q000628:therapy; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011518:Proto-Oncogene Proteins / Q000032:analysis; D051560:Proto-Oncogene Proteins c-bcl-6; D014157:Transcription Factors / Q000032:analysis; D019043:Vascular Neoplasms / Q000378:metabolism / Q000473:pathology* / Q000628:therapy; D000099218:Interferon Regulatory Factor-4
D018941:Antigens, CD19; D018951:Antigens, CD20; D018956:CD5 Antigens; D004268:DNA-Binding Proteins; D050835:Interferon Regulatory Factors; D017493:Leukocyte Common Antigens; D011518:Proto-Oncogene Proteins; D051560:Proto-Oncogene Proteins c-bcl-6; D014157:Transcription Factors; D000099218:Interferon Regulatory Factor-4